Holtham Angela 4

What Happened Angela Holtham, a director of Oncolytics Biotech Inc. (ONCY), received a grant of 30,000 derivative securities on June 1, 2026. The Form 4 reports the acquisition amount as $0 because this is an award/option grant; the footnote states the option's exercise price equals the issuer's closing common stock price on the Nasdaq on the grant date (June 1, 2026). This was an award (neither an open-market purchase nor a sale), so it does not represent an immediate cash purchase or disposition.

Key Details

• Transaction date: 2026-06-01; Form 4 filed: 2026-06-03 (appears timely).
• Grant: 30,000 derivative securities reported as acquired at $0.00 on the Form 4.
• Exercise price: equal to the issuer's closing price on Nasdaq on 2026-06-01 (per footnote).
• Vesting: Options vest in three equal annual installments, with first tranche on June 1, 2027, subject to continued service (per footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax withholding, cashless exercise, or late filing in the excerpt.

Context This was an equity award (stock option grant) to a director that vests over time; no shares were reported sold or immediately issued. For retail investors, such grants are common as compensation and do not by themselves signal buying or selling pressure—any future impact depends on vesting, exercise, and whether the underlying shares are later sold.